You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 7,205,302

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,205,302 protect, and when does it expire?

Patent 7,205,302 protects UPTRAVI and is included in two NDAs.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 7,205,302

Title:	Heterocyclic compound derivatives and medicines
Abstract:	The present invention provides a compound which is useful as a PGI.sub.2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: ##STR00001## (R.sup.1 and R.sup.2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR.sup.5, O, S, or ethylene, R.sup.5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH.sub.2, R.sup.3 and R.sup.4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventor(s):	Asaki; Tetsuo (Kyoto, JP), Hamamoto; Taisuke (Osaka, JP), Kuwano; Keiichi (Osaka, JP)
Assignee:	Nippon Shinyaku Co., Ltd. (Kyoto, JP)
Application Number:	10/476,196
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,205,302
Patent Claim Types: see list of patent claims	Composition; Compound; Use;

Drugs Protected by US Patent 7,205,302

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG	⤷ Sign Up
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG	⤷ Sign Up
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG	⤷ Sign Up
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-003	Dec 21, 2015	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,205,302

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2001-129765	Apr 26, 2001

PCT Information
PCT Filed	April 25, 2002	PCT Application Number:	PCT/JP02/04118
PCT Publication Date:	November 07, 2002	PCT Publication Number:	WO02/088084

International Family Members for US Patent 7,205,302

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1400518	⤷ Sign Up	300836	Netherlands	⤷ Sign Up
European Patent Office	1400518	⤷ Sign Up	93266	Luxembourg	⤷ Sign Up
European Patent Office	1400518	⤷ Sign Up	CA 2016 00048	Denmark	⤷ Sign Up
European Patent Office	1400518	⤷ Sign Up	16C0042	France	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.